文献速递浆细胞疾病

外周血单核细胞计数是多发性骨髓瘤的动态预后生物标志物

Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma.
PubMed 文献 · Blood Adv · 2023-01-01

该回顾性研究分析了2000至2019年间美国退伍军人事务部医院新诊断的10822例多发性骨髓瘤患者,发现诊断时绝对单核细胞计数(AMC)异常者占25.3%,且与较差的总生存期(OS)相关;诊断后2.5年内AMC异常同样与较差OS相关;异常AMC与较差OS的关联独立于国际分期系统(ISS)和乳酸脱氢酶(LDH)等已验证的预后标志物。

要点

  • 诊断时AMC异常(<0.2或≥0.8×10³/mm³)见于25.3%的新诊断多发性骨髓瘤患者。
  • 诊断时AMC低、重度升高、升高和正常组的中位OS分别为2.3、2.7、3.1和3.6年(P<0.001)。
  • 诊断时AMC正常但诊断后1年以上出现AMC异常者,OS仍劣于AMC持续正常者。

核心结论

  • 诊断时及诊断后2.5年内异常AMC与较差OS相关,且独立于ISS和LDH等已验证预后标志物。

研究设计与样本

  • 回顾性分析2000至2019年间在退伍军人事务部医院新诊断的10822例多发性骨髓瘤患者。
  • 获取最接近诊断时及之后每3个月直至2.5年的AMC。
  • 按AMC水平分为4组:低(<0.2×10³/mm³)、正常(0.2-<0.8×10³/mm³)、升高(0.8-<1.25×10³/mm³)和重度升高(≥1.25×10³/mm³)。

主要发现

  • 诊断时AMC异常者占25.3%,与较差OS相关。
  • 诊断时AMC低、重度升高、升高和正常组的中位OS分别为2.3、2.7、3.1和3.6年(P<0.001)。
  • 诊断后2.5年时,上述四组的中位OS分别为2.0、2.6、3.4和3.9年(P<0.001)。
  • 诊断时AMC正常但诊断后1年以上出现AMC异常者,OS劣于AMC持续正常者。
  • 异常AMC与较差OS的关联独立于ISS和LDH等已验证预后标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the growing knowledge of multiple myeloma (MM) pathobiology and the introduction of novel therapies, risk stratification continues to evolve. Myeloid-derived suppressor cells and tumor-associated macrophages, derived from peripheral blood monocytes, support malignant plasma cell proliferation in the bone marrow. Because peripheral blood absolute monocyte count (AMC) is thought to reflect the bone marrow microenvironment, we sought to evaluate the prognostic significance of AMC in MM. We retrospectively analyzed 10 822 patients newly diagnosed with MM between 2000 and 2019 at Veteran's Administration hospitals. We obtained AMC closest to diagnosis and every 3 months thereafter up to 2.5 years. Patients were stratified into 4 groups: low, normal, elevated, and severely elevated AMC (<0.2, 0.2-<0.8, 0.8-<1.25, and ≥1.25 × 103/mm3, respectively). Abnormal AMC at diagnosis was observed in 25.3% of the patients and was associated with an inferior overall survival (OS). In patients with low, severely elevated, elevated, and normal AMC, respectively, median OS at diagnosis was 2.3, 2.7, 3.1, and 3.6 years (P < .001) and at 2.5 years was 2.0, 2.6, 3.4, and 3.9 years (P < .001). Patients with normal AMC at diagnosis who developed an abnormal AMC >1 year after diagnosis also had an inferior OS relative to patients who maintained a normal AMC. Abnormal AMC was also associated with inferior OS independent of validated prognostic markers, including the international staging system and lactate dehydrogenase. Our findings provide novel clues for future prospective studies on the functional role of monocytes in MM, which could be a readily available metric for risk stratification.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Edwards CV, Hassan H, Yildirim C, et al. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023. PMID: 36409606. doi:10.1182/bloodadvances.2022008021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。